Regenerative in-bone micro-pharmacies engineered for targeted local drug delivery.
Market-Entry Product
OsteoFlux™ is Elutiq's first clinical product, designed to deliver localized antibiotic therapy directly within the bone defect site as part of a single-stage surgical approach. By combining natural bone architecture with proprietary drug-delivery technology, OsteoFlux™ enables surgeons to manage infection locally while simultaneously promoting bone regeneration in complex fractures and osteomyelitis.
Its controlled local release strategy is engineered to provide sustained antimicrobial activity without compromising the biological integrity of the graft. OsteoFlux™ represents the first product of Elutiq's multi-asset orthopedic drug-device platform.
Regulatory pathway
United States: FDA De Novo
European Union: MDR Class III
Designed to integrate into existing reimbursement frameworks in both the United States and Germany, facilitating clinical adoption.
Flagship Product
OsteoSyn™ introduces synchronized multi-antibiotic therapy designed for the treatment of chronic and resistant bone infections. Its engineered elution profile enables surgeons to target bacterial infection and biofilms while supporting bone regeneration within the same surgical procedure, particularly in biologically compromised environments.
By enabling limb salvage in cases with high amputation risk, OsteoSyn™ aims to redefine treatment options for severe orthopedic infections.
Regulatory pathway
United States: FDA PMA / FDA IND
European Union: Medicinal Product MAA
Development includes First-in-Human clinical studies.
Platform Potential
The platform is drug-agnostic, designed for localized multi-drug delivery, and expandable across orthopedics, oncology, dental applications, and rare bone diseases.
Osteolytic tumors and Metastatic Bone Lesions.
Localized disease control and bone repair within one surgical approach.
Market-Entry Product
OsteoFlux™ is Elutiq's first clinical product, designed to deliver localized antibiotic therapy directly within the bone defect site as part of a single-stage surgical approach.
By combining natural bone architecture with proprietary drug-delivery technology, OsteoFlux™ enables surgeons to manage infection locally while simultaneously promoting bone regeneration in complex fractures and osteomyelitis.
Regulatory pathway
United States: FDA De Novo
Designed to integrate into existing reimbursement frameworks.
Flagship Product
OsteoSyn™ introduces synchronized multi-antibiotic therapy designed for the treatment of chronic and resistant bone infections.
By enabling limb salvage in cases with high amputation risk, OsteoSyn™ aims to redefine treatment options for severe orthopedic infections.
Regulatory pathway
United States: FDA PMA / FDA IND
European Union: Medicinal Product MAA
Development includes First-in-Human clinical studies.
Platform Potential
The platform is drug-agnostic, designed for localized multi-drug delivery, and expandable across orthopedics, oncology, dental applications, and rare bone diseases.
Osteolytic tumors Metastatic Bone Lesions.
Localized disease control and bone repair within one surgical approach.
